MX366159B - Liberacion autorregulada de ingrediente farmaceutico activo. - Google Patents

Liberacion autorregulada de ingrediente farmaceutico activo.

Info

Publication number
MX366159B
MX366159B MX2015006613A MX2015006613A MX366159B MX 366159 B MX366159 B MX 366159B MX 2015006613 A MX2015006613 A MX 2015006613A MX 2015006613 A MX2015006613 A MX 2015006613A MX 366159 B MX366159 B MX 366159B
Authority
MX
Mexico
Prior art keywords
ingredient
active pharmaceutical
self
pharmaceutical ingredient
regulated release
Prior art date
Application number
MX2015006613A
Other languages
English (en)
Other versions
MX2015006613A (es
Inventor
W Brzeczko Albert
Gary Hollenbeck R
Original Assignee
Acura Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acura Pharmaceuticals Inc filed Critical Acura Pharmaceuticals Inc
Publication of MX2015006613A publication Critical patent/MX2015006613A/es
Publication of MX366159B publication Critical patent/MX366159B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Oil, Petroleum & Natural Gas (AREA)

Abstract

Se proporciona una composición farmacéutica que evita el abuso, que incluye un ingrediente farmacéuticamente activo, un ingrediente soluble en ácido y un ingrediente amortiguador; en donde el ingrediente soluble en ácido y el ingrediente amortiguador retardan la liberación del ingrediente farmacéutico activo cuando la composición se ingiere en exceso de una dosis destinada.
MX2015006613A 2012-11-30 2013-11-27 Liberacion autorregulada de ingrediente farmaceutico activo. MX366159B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261731901P 2012-11-30 2012-11-30
PCT/US2013/072249 WO2014085599A1 (en) 2012-11-30 2013-11-27 Self-regulated release of active pharmaceutical ingredient

Publications (2)

Publication Number Publication Date
MX2015006613A MX2015006613A (es) 2015-11-16
MX366159B true MX366159B (es) 2019-07-01

Family

ID=50826034

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015006613A MX366159B (es) 2012-11-30 2013-11-27 Liberacion autorregulada de ingrediente farmaceutico activo.
MX2019007956A MX392839B (es) 2012-11-30 2013-11-27 Liberacion autorregulada de ingrediente farmaceutico activo.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019007956A MX392839B (es) 2012-11-30 2013-11-27 Liberacion autorregulada de ingrediente farmaceutico activo.

Country Status (11)

Country Link
US (8) US9101636B2 (es)
EP (2) EP2925304B1 (es)
JP (8) JP5922851B2 (es)
CN (3) CN108743549B (es)
AU (5) AU2013352162B2 (es)
CA (1) CA2892908C (es)
ES (1) ES2691982T3 (es)
IL (1) IL238713A0 (es)
MX (2) MX366159B (es)
RU (2) RU2018141241A (es)
WO (1) WO2014085599A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877241B2 (en) 2003-03-26 2014-11-04 Egalet Ltd. Morphine controlled release system
NZ580972A (en) 2007-06-04 2012-02-24 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
WO2010089132A1 (en) 2009-02-06 2010-08-12 Egalet A/S Immediate release composition resistant to abuse by intake of alcohol
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
ES2691982T3 (es) * 2012-11-30 2018-11-29 Acura Pharmaceuticals, Inc. Liberación autorregulada de un principio activo farmacéutico
EP2968178B1 (en) * 2013-03-15 2019-10-09 Inspirion Delivery Sciences LLC Pharmaceuticals comprising a ph-dependent component and ph-raising agent
CA2938699A1 (en) 2014-02-05 2015-08-13 Kashiv Pharma Llc Abuse-resistant drug formulations with built-in overdose protection
US9616029B2 (en) * 2014-03-26 2017-04-11 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release coated reservoir solid dosage form
WO2015191501A1 (en) 2014-06-09 2015-12-17 Acura Pharmaceuticals, Inc. Methods and compositions for interfering with extraction or conversion of a drug susceptible to abuse
CN105682649A (zh) * 2014-07-15 2016-06-15 艾萨·欧蒂迪 减少过剂量的组合物和方法
CA2910865C (en) 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
CA2955477A1 (en) * 2014-09-27 2016-03-31 Jayendrakumar Dasharathlal PATEL Pharmaceutical abuse deterrent composition
WO2016094358A1 (en) * 2014-12-08 2016-06-16 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
EP3231420A1 (en) 2016-02-29 2017-10-18 G.L. Pharma GmbH Abuse-deterrent pharmaceutical compositions
EP3210630A1 (en) 2016-02-29 2017-08-30 G.L. Pharma GmbH Abuse-deterrent pharmaceutical compositions
EP3210596A1 (en) 2016-02-29 2017-08-30 G.L. Pharma GmbH Abuse-deterrent pharmaceutical composition
AU2018243657B2 (en) * 2017-03-31 2021-09-16 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceuticals ingredients
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
CA3067945A1 (en) 2017-06-23 2018-12-27 Sun Pharma Advanced Research Company Limited Abuse deterrent oral solid dosage form
JP6371928B1 (ja) * 2018-02-23 2018-08-08 株式会社 東亜産業 電子タバコ用充填物およびそれを用いた電子タバコカートリッジ
JP7370125B2 (ja) * 2018-11-09 2023-10-27 日本化薬株式会社 エルロチニブを有効成分とする医薬錠剤
JP7370126B2 (ja) * 2018-11-27 2023-10-27 日本化薬株式会社 エルロチニブを有効成分とする医薬錠剤
US10792262B1 (en) * 2019-07-29 2020-10-06 Saol International Limited Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
JP2023553010A (ja) 2020-12-03 2023-12-20 バテル・メモリアル・インスティテュート 非ウイルス性送達のためのポリマーナノ粒子およびｄｎａナノ構造組成物ならびに方法
EP4320233A4 (en) 2021-04-07 2025-08-13 Battelle Memorial Institute RAPID DESIGN, BUILD, TEST, AND LEARNING TECHNOLOGIES TO IDENTIFY AND USE NON-VIRAL VECTORS
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
WO2025122954A1 (en) 2023-12-08 2025-06-12 Battelle Memorial Institute Use of dna origami nanostructures for molecular information based data storage systems
CZ2024189A3 (cs) * 2024-05-13 2025-11-26 Zentiva, K.S. Farmaceutická kompozice alprazolamu

Family Cites Families (225)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065143A (en) 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
US3260646A (en) 1962-10-19 1966-07-12 Ferring Ab Medication with mechanism to prevent overdosage
GB1428361A (en) 1972-02-15 1976-03-17 Grant A Safeguarded medicinal compositions
DE2530563C2 (de) 1975-07-09 1986-07-24 Bayer Ag, 5090 Leverkusen Analgetische Arzneimittel mit vermindertem Mißbrauchspotential
US4175119A (en) 1978-01-11 1979-11-20 Porter Garry L Composition and method to prevent accidental and intentional overdosage with psychoactive drugs
US4221778A (en) 1979-01-08 1980-09-09 Pennwalt Corporation Prolonged release pharmaceutical preparations
US4457933A (en) 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4459278A (en) 1983-03-07 1984-07-10 Clear Lake Development Group Composition and method of immobilizing emetics and method of treating human beings with emetics
JPS59193831A (ja) * 1983-04-18 1984-11-02 Sankyo Co Ltd 腸溶性製剤の製造法
US4599342A (en) 1984-01-16 1986-07-08 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
US4610870A (en) 1984-10-05 1986-09-09 E. R. Squibb & Sons, Inc. Controlled release formulation
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4666705A (en) 1985-06-03 1987-05-19 E. R. Squibb & Sons, Inc. Controlled release formulation
US4800083A (en) * 1986-10-20 1989-01-24 R. P. Scherer Corporation Sustained release method and product
US4801461A (en) 1987-01-28 1989-01-31 Alza Corporation Pseudoephedrine dosage form
US4915952A (en) 1987-02-27 1990-04-10 Alza Corporation Composition comprising drug, HPC, HPMC and PEO
US5073380A (en) 1987-07-27 1991-12-17 Mcneil-Ppc, Inc. Oral sustained release pharmaceutical formulation and process
US5330766A (en) 1989-01-06 1994-07-19 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5059600A (en) 1989-03-31 1991-10-22 Yale University Treating habit disorders
US5114942A (en) 1989-03-31 1992-05-19 Yale University Treating habit disorders
US5084278A (en) 1989-06-02 1992-01-28 Nortec Development Associates, Inc. Taste-masked pharmaceutical compositions
US5075114A (en) 1990-05-23 1991-12-24 Mcneil-Ppc, Inc. Taste masking and sustained release coatings for pharmaceuticals
US5284662A (en) 1990-10-01 1994-02-08 Ciba-Geigy Corp. Oral osmotic system for slightly soluble active agents
US5098715A (en) 1990-12-20 1992-03-24 Burroughs Wellcome Co. Flavored film-coated tablet
US5273758A (en) 1991-03-18 1993-12-28 Sandoz Ltd. Directly compressible polyethylene oxide vehicle for preparing therapeutic dosage forms
US5405617A (en) 1991-11-07 1995-04-11 Mcneil-Ppc, Inc. Aliphatic or fatty acid esters as a solventless carrier for pharmaceuticals
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5431916A (en) 1993-04-29 1995-07-11 The Procter & Gamble Company Pharmaceutical compositions and process of manufacture thereof
US5484606A (en) 1994-01-24 1996-01-16 The Procter & Gamble Company Process for reducing the precipitation of difficulty soluble pharmaceutical actives
GB9401894D0 (en) 1994-02-01 1994-03-30 Rhone Poulenc Rorer Ltd New compositions of matter
US5395626A (en) 1994-03-23 1995-03-07 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
JPH10501235A (ja) 1994-06-03 1998-02-03 ザ、プロクター、エンド、ギャンブル、カンパニー 速溶解性剤形
US5460826A (en) 1994-06-27 1995-10-24 Alza Corporation Morphine therapy
US5660859A (en) 1994-12-29 1997-08-26 Mcneil-Ppc, Inc. Gelling agent for polyethylene glycol
NZ280610A (en) 1994-12-29 1997-08-22 Mcneil Ppc Inc Soft gelatin-like pharmaceutical carrier: gelled polyethylene glycol and dispersed active agent
IL116674A (en) 1995-01-09 2003-05-29 Mendell Co Inc Edward Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof
US5556879A (en) 1995-03-01 1996-09-17 Rhone Merieux, Inc. Aqueous spectinomycin borate solutions
US5558879A (en) 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
US5654005A (en) 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
US5807579A (en) 1995-11-16 1998-09-15 F.H. Faulding & Co. Limited Pseudoephedrine combination pharmaceutical compositions
BR9708559A (pt) 1996-04-10 1999-08-03 Warner Lambert Co Desnaturantes para sais de amina simpatomimetica
US5858409A (en) 1996-04-17 1999-01-12 Fmc Corporation Hydrolyzed cellulose granulations for pharmaceuticals
EP2272536B1 (en) 1996-06-26 2016-05-04 Board of Regents, The University of Texas System Hot-melt extrudable Pharmaceutical formulation
US5919481A (en) 1996-06-28 1999-07-06 Ncneil-Ppc, Inc. Fill material for soft gelatin pharmaceutical dosage form
US6024980A (en) 1996-06-28 2000-02-15 Mcneil-Ppc, Inc. Multiphase soft gelatin dosage form
US6361796B1 (en) 1996-10-25 2002-03-26 Shire Laboratories, Inc. Soluble form osmotic dose delivery system
US6027746A (en) 1997-04-23 2000-02-22 Warner-Lambert Company Chewable soft gelatin-encapsulated pharmaceutical adsorbates
US6210710B1 (en) 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
US6004582A (en) 1997-05-30 1999-12-21 Laboratorios Phoenix U.S.A, Inc. Multi-layered osmotic device
US6153621A (en) 1997-06-23 2000-11-28 The University Of Kentucky Research Foundation Combined antagonist compositions
US5895663A (en) 1997-07-31 1999-04-20 L. Perrigo Company Pseudoephedrine hydrochloride extended-release tablets
DE19740983A1 (de) 1997-09-18 1999-04-08 Warner Lambert Co N D Ges D St Verfahren zur Erschwerung der Extraktion von Wirkstoffen aus Tabletten
US6607751B1 (en) 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
US5955107A (en) 1997-12-12 1999-09-21 Fmc Corporation Pharmaceutical suspension tablet compositions
US20030059471A1 (en) 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
BR9813826A (pt) 1997-12-22 2000-10-10 Euro Celtique Sa Potencial de uso abusivo de administração oral de opióide analgésico
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
US6432442B1 (en) 1998-02-23 2002-08-13 Mcneil-Ppc, Inc. Chewable product
US6245357B1 (en) 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
AU753241C (en) 1998-06-11 2003-05-08 Pharmacia & Upjohn Company Tablet formation
DK1091733T3 (da) 1998-07-01 2006-04-03 Warner Lambert Co (-)-Pseudoephedrin som et sympatomimetisk lægemiddel
US6541520B1 (en) 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
US6270790B1 (en) 1998-08-18 2001-08-07 Mxneil-Ppc, Inc. Soft, convex shaped chewable tablets having reduced friability
US5997905A (en) 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
GT199900148A (es) 1998-09-10 2001-02-28 Desnaturalizantes para las sales aminas simpaticomimeticas.
SE9803239D0 (sv) 1998-09-24 1998-09-24 Diabact Ab Composition for the treatment of acute pain
SE9803240D0 (sv) 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
US7906143B1 (en) 1998-10-05 2011-03-15 Intellipharmaceutics Corp Controlled release pharmaceutical delivery device and process for preparation thereof
EP1005863A1 (en) 1998-12-04 2000-06-07 Synthelabo Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof
CA2355777A1 (en) 1998-12-15 2000-06-22 Wm. Wrigley Jr. Company Controlling release of active agents from a chewing gum coating
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030170181A1 (en) 1999-04-06 2003-09-11 Midha Kamal K. Method for preventing abuse of methylphenidate
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US6500459B1 (en) 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
US6340471B1 (en) 1999-12-30 2002-01-22 Alvin Kershman Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals
US6541025B1 (en) 1999-12-30 2003-04-01 Shear/Kershman Laboratories, Inc. Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals
US6613357B2 (en) 2000-01-13 2003-09-02 Osmotica Corp. Osmotic device containing pseudoephedrine and an H1 antagonist
US6352721B1 (en) 2000-01-14 2002-03-05 Osmotica Corp. Combined diffusion/osmotic pumping drug delivery system
US6491949B2 (en) 2000-01-14 2002-12-10 Osmotica Corp. Osmotic device within an osmotic device
US6277409B1 (en) 2000-02-11 2001-08-21 Mcneil-Ppc, Inc. Protective coating for tablet
DE10010524C2 (de) * 2000-03-07 2002-08-29 Freudenberg Carl Kg Abstreifer mit integrierter Dichtung
US6551617B1 (en) 2000-04-20 2003-04-22 Bristol-Myers Squibb Company Taste masking coating composition
US20030129131A1 (en) * 2000-06-21 2003-07-10 Makoto Inada Preparations for measuring gastric ph value and method of measuring gastric ph value by using the same
US6607748B1 (en) 2000-06-29 2003-08-19 Vincent Lenaerts Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
US6375982B1 (en) 2000-07-05 2002-04-23 Capricorn Pharma, Inc. Rapid-melt semi-solid compositions, methods of making same and method of using same
US20100010101A1 (en) 2000-07-05 2010-01-14 Capricorn Pharma, Inc. Rapid-Melt Compositions and Methods of Making Same
US20020022057A1 (en) 2000-08-17 2002-02-21 Battey Alyce S. Oral delivery of pharmaceuticals via encapsulation
US20030049320A1 (en) 2000-12-18 2003-03-13 Wockhardt Limited Novel in-situ forming controlled release microcarrier delivery system
US20020119196A1 (en) 2000-12-21 2002-08-29 Narendra Parikh Texture masked particles containing an active ingredient
US6800668B1 (en) 2001-01-19 2004-10-05 Intellipharmaceutics Corp. Syntactic deformable foam compositions and methods for making
US6559159B2 (en) 2001-02-01 2003-05-06 Research Triangle Institute Kappa opioid receptor ligands
EP1240897B1 (en) 2001-03-14 2006-06-21 Pfizer Products Inc. Pharmaceutical tablet and process for making thereof
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
CA2778114A1 (en) 2001-05-11 2002-11-21 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
US20030064122A1 (en) 2001-05-23 2003-04-03 Endo Pharmaceuticals, Inc. Abuse resistant pharmaceutical composition containing capsaicin
EP1390015A1 (en) 2001-05-31 2004-02-25 Cima Labs Inc. Taste-masking of highly water-soluble drugs
US6524618B1 (en) 2001-06-12 2003-02-25 Vijai Kumar Directly compressible extended-release matrix formulation for metformin hydrochloride
US20030021841A1 (en) 2001-07-02 2003-01-30 Matharu Amol Singh Pharmaceutical composition
WO2003013481A1 (en) 2001-08-03 2003-02-20 Bakulesh Mafatlal Khamar The process of manufacturing pharmaceutical composition with increased content of poorly soluble pharmaceutical ingredients
US7141250B2 (en) 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US7157103B2 (en) 2001-08-06 2007-01-02 Euro-Celtique S.A. Pharmaceutical formulation containing irritant
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
US7332182B2 (en) 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
US7144587B2 (en) 2001-08-06 2006-12-05 Euro-Celtique S.A. Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
US20030099711A1 (en) 2001-08-29 2003-05-29 David Meadows Sustained release preparations
US20030049272A1 (en) 2001-08-30 2003-03-13 Yatindra Joshi Pharmaceutical composition which produces irritation
US20030050620A1 (en) 2001-09-07 2003-03-13 Isa Odidi Combinatorial type controlled release drug delivery device
US20030068276A1 (en) 2001-09-17 2003-04-10 Lyn Hughes Dosage forms
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
CA2459976A1 (en) 2001-09-26 2003-04-03 Penwest Pharmaceuticals Company Opioid formulations having reduced potential for abuse
US6592901B2 (en) 2001-10-15 2003-07-15 Hercules Incorporated Highly compressible ethylcellulose for tableting
CA2466036C (en) 2001-10-22 2012-04-24 Taro Pharmaceutical Industries Ltd. Taste masking spill-resistant formulation
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
WO2003039561A1 (en) 2001-11-02 2003-05-15 Elan Corporation, Plc Pharmaceutical composition
US7101572B2 (en) 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
KR100540035B1 (ko) 2002-02-01 2005-12-29 주식회사 태평양 다단계 경구 약물 방출 제어 시스템
AU2003224419A1 (en) 2002-02-20 2003-09-09 Strides Arcolab Limited Orally administrable pharmaceutical formulation
US8323692B2 (en) 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
US7708771B2 (en) 2002-02-26 2010-05-04 Endovascular Technologies, Inc. Endovascular graft device and methods for attaching components thereof
US6753009B2 (en) 2002-03-13 2004-06-22 Mcneil-Ppc, Inc. Soft tablet containing high molecular weight polyethylene oxide
US20050106249A1 (en) 2002-04-29 2005-05-19 Stephen Hwang Once-a-day, oral, controlled-release, oxycodone dosage forms
US7157100B2 (en) 2002-06-04 2007-01-02 J.B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical composition for controlled drug delivery system
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
EP1524963A2 (en) 2002-06-26 2005-04-27 Cadila Healthcare Ltd. Novel floating dosage form
SI1551372T1 (en) 2002-09-20 2018-08-31 Alpharma Pharmaceuticals Llc SUBVENCATION DATA AND RELATED CONSTRUCTIONS AND PROCEDURES
WO2004026256A2 (en) 2002-09-20 2004-04-01 Alpharma, Inc. Sustained-release opioid formulations and methods of use
US20040081695A1 (en) 2002-09-28 2004-04-29 Sowden Harry S Dosage forms having an inner core and an outer shell
ES2310686T3 (es) 2002-10-25 2009-01-16 Labopharm Inc. Composiciones de liberacion controlada.
DE10250084A1 (de) 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
CA2505850C (en) 2002-11-13 2011-01-04 Synthes (U.S.A.) Articular facet interference screw
WO2004045551A2 (en) 2002-11-15 2004-06-03 Branded Products For The Future Pharmaceutical composition
US20040109889A1 (en) 2002-12-04 2004-06-10 Bunick Frank J. Surface treatment composition for soft substrates
US8293799B2 (en) 2003-12-29 2012-10-23 Osmotica Keresleedelmo és Szolgáltató KFT Osmotic device containing a venlafaxine salt and a salt having an ion in common
US7524515B2 (en) 2003-01-10 2009-04-28 Mutual Pharmaceuticals, Inc. Pharmaceutical safety dosage forms
US20040185097A1 (en) 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
EP2186510B1 (en) 2003-03-26 2013-07-10 Egalet Ltd. Matrix compositions for controlled delivery of drug substances
AU2004238321B2 (en) 2003-05-07 2009-08-27 Samyang Biopharmaceuticals Corporation Highly plastic granules for making fast melting tablets
US8906413B2 (en) 2003-05-12 2014-12-09 Supernus Pharmaceuticals, Inc. Drug formulations having reduced abuse potential
US20040265372A1 (en) 2003-06-27 2004-12-30 David Wynn Soft tablet containing high molecular weight cellulosics
DE102004020220A1 (de) 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
BRPI0413353A (pt) 2003-08-06 2006-10-10 Nirmal Mulye composição farmacêutica contendo droga solúvel em água
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
AU2004264974A1 (en) 2003-08-15 2005-02-24 Arius Two, Inc. Adhesive bioerodible transmucosal drug delivery system
US7611728B2 (en) 2003-09-05 2009-11-03 Supernus Pharmaceuticals, Inc. Osmotic delivery of therapeutic compounds by solubility enhancement
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
TWI365880B (en) 2004-03-30 2012-06-11 Euro Celtique Sa Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone and oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oeal dosage form and pharmaceutically acceptable package having less than 25 pp
ES2385832T3 (es) 2004-05-21 2012-08-01 Accu-Break Technologies, Inc. Comprimidos farmacéuticos que presentan un segmento relativamente inactivo
WO2005115345A1 (en) 2004-05-28 2005-12-08 Imaginot Pty Ltd Oral therapeutic compound delivery system
US7045425B2 (en) 2004-06-30 2006-05-16 Texas Instruments Incorporated Bird's beak-less or STI-less OTP EPROM
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
WO2006017159A1 (en) 2004-07-09 2006-02-16 Drugtech Corporation Controlled phase composition technology as an improved process for protection of drugs
WO2006008739A2 (en) 2004-07-19 2006-01-26 Elutex Ltd. Modified conductive surfaces having active substances attached thereto
US20060018837A1 (en) 2004-07-26 2006-01-26 Victory Pharma, Inc. Pharmaceutical compositions and methods for the prevention of drug misuse
US20060093631A1 (en) 2004-10-29 2006-05-04 Buehler Gail K Dye-free pharmaceutical suspensions and related methods
US20060110327A1 (en) 2004-11-24 2006-05-25 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20080152595A1 (en) 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20060177380A1 (en) 2004-11-24 2006-08-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
JP2008534591A (ja) 2005-03-29 2008-08-28 マクニール−ピーピーシー・インコーポレーテツド 疎水性溶媒内に親水性薬剤を有する組成物
EP1906937B1 (en) 2005-07-22 2016-10-19 Rubicon Research Pvt Ltd. Novel dispersible tablet composition
US9125833B2 (en) 2005-11-02 2015-09-08 Relmada Therapeutics, Inc. Multimodal abuse resistant and extended release opioid formulations
WO2007054976A2 (en) 2005-11-08 2007-05-18 Panacea Biotec Ltd. Lipid based controlled release pharmaceutical composition
EP3263117A1 (en) 2005-11-28 2018-01-03 Imaginot Pty Ltd. Oral therapeutic compound delivery system
CN101322156B (zh) 2005-12-08 2011-09-21 皇家飞利浦电子股份有限公司 实现对图像配准变换的选择的系统和方法
US20070134493A1 (en) 2005-12-08 2007-06-14 Kanji Meghpara Compositions and capsules with stable hydrophilic layers
US20090317355A1 (en) 2006-01-21 2009-12-24 Abbott Gmbh & Co. Kg, Abuse resistant melt extruded formulation having reduced alcohol interaction
FR2898056B1 (fr) 2006-03-01 2012-01-20 Ethypharm Sa Comprimes resistant a l'ecrasement destines a eviter le detournement illicite
ATE536867T1 (de) 2006-03-16 2011-12-15 Tris Pharma Inc Modifizierte freisetzungsformulierungen mit arznei-ion-austausch-harzkomplexen
NZ572106A (en) 2006-03-31 2010-12-24 Rubicon Res Private Ltd Directly compressible composite for orally disintegrating tablets
US10960077B2 (en) * 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US20070292510A1 (en) 2006-06-19 2007-12-20 Hugh Huang Enteric coated particles containing an active ingredient
EP2046299A1 (en) 2006-07-11 2009-04-15 Mutual Pharmaceutical Company, Inc. Controlled-release formulations
US20080014228A1 (en) 2006-07-14 2008-01-17 Olivia Darmuzey Solid form
US20080075771A1 (en) * 2006-07-21 2008-03-27 Vaughn Jason M Hydrophilic opioid abuse deterrent delivery system using opioid antagonists
WO2008012010A1 (en) * 2006-07-27 2008-01-31 Ucb Pharma, S.A. Fused oxazoles & thiazoles as histamine h3- receptor ligands
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
WO2008027442A2 (en) * 2006-08-30 2008-03-06 Theraquest Biosciences, Llc Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use
EP2068844A4 (en) 2006-09-04 2013-01-23 Panacea Biotec Ltd PROGRAMMABLE RELEASE TECHNIQUE BY FLOATING SYSTEM
US20080260837A1 (en) 2007-04-20 2008-10-23 Qpharma, L.L.C. Physically stable aqueous suspensions of active pharmaceuticals
CN101677945A (zh) 2007-05-08 2010-03-24 赫尔克里士公司 坚固的快速崩解片剂制剂
WO2008140459A1 (en) 2007-05-16 2008-11-20 Fmc Corporation Solid form
WO2008140460A1 (en) 2007-05-16 2008-11-20 Fmc Corporation Solid form
EP2167049B1 (en) 2007-06-04 2016-08-31 Shear/Kershman Laboratories, Inc. Tamper resistant lipid-based oral dosage form for opioid agonists
US20090004281A1 (en) 2007-06-26 2009-01-01 Biovail Laboratories International S.R.L. Multiparticulate osmotic delivery system
HRP20191104T1 (hr) 2007-09-25 2019-09-20 Solubest Ltd. Pripravci koji sadrže lipofilne aktivne spojeve i postupak za njihovu pripremu
US20090081291A1 (en) 2007-09-26 2009-03-26 Gin Jerry B Sustained Release Dosage Forms For Delivery of Agents to an Oral Cavity of a User
WO2009043844A2 (en) 2007-10-01 2009-04-09 Laboratorios Lesvi, S.L. Orodispersible tablets
US20110020440A1 (en) 2007-11-19 2011-01-27 Cadila Pharmaceuticals Limited Stable solutions of sparingly soluble actives
CN101969930A (zh) 2007-12-17 2011-02-09 莱博法姆公司 防滥用控制释放制剂
DK2229158T3 (en) 2007-12-20 2016-12-12 Fertin Pharma As Compressed chewing gum tablet
DK2229156T3 (en) 2007-12-20 2017-02-06 Fertin Pharma As CHEW GUM TABLE AND PROCEDURE FOR DOSING PHARMACEUTICAL ACTIVE INGREDIENTS IN SUCH CHEW GUM TABLE
DK2229157T3 (en) 2007-12-20 2016-12-05 Fertin Pharma As Compressed chewing gum tablet
PE20091550A1 (es) 2008-01-11 2009-10-03 Cipla Ltd Composicion farmaceutica extruida/granulada en caliente
JP5774853B2 (ja) 2008-01-25 2015-09-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 医薬投薬形
BRPI0908114A2 (pt) 2008-02-15 2015-10-06 Sun Pharma Advanced Res Co Ltd tabuleta oral de liberação controlada
US8420700B1 (en) 2008-06-04 2013-04-16 James M. Bausch Tamper resistant lipid-based oral dosage form for sympathomimetic amines
US20100136110A1 (en) * 2008-09-30 2010-06-03 Astellas Pharma Inc. Granular pharmaceutical composition for oral administration
MX2011003984A (es) 2008-10-14 2011-05-10 Mcneil Ab Forma de dosis intraoral de multiples porciones y uso de esta.
US20100099696A1 (en) * 2008-10-16 2010-04-22 Anthony Edward Soscia Tamper resistant oral dosage forms containing an embolizing agent
SE533001C2 (sv) 2008-10-17 2010-06-08 Scania Cv Abp En anslutningsanordning
EP2198859A1 (en) 2008-12-17 2010-06-23 Losan Pharma GmbH Melt-coated pharmaceutical composition with fast release
NO2403482T3 (es) * 2009-03-04 2018-05-26
US20100260842A1 (en) 2009-04-06 2010-10-14 Rashmi Nair Pseudoephedrine pharmaceutical formulations
AR076540A1 (es) * 2009-05-01 2011-06-22 Eurand Inc Composiciones de comprimidos de desintegracion oral que comprenden combinaciones de analgesicos no- opioides y opioides, forma de dosificacion. metodo de preparacion. metodo para tratar dolor
BRPI0925100A2 (pt) * 2009-06-02 2016-07-19 Dow Global Technologies Llc forma de dosagem osmótica e processo para preparar uma forma de dosagem osmótica
EP2477614A2 (en) 2009-09-17 2012-07-25 Cadila Healthcare Limited Pharmaceutical compositions for reducing alcohol-induced dose dumping
US8901113B2 (en) 2009-09-30 2014-12-02 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
WO2011066980A2 (en) * 2009-12-04 2011-06-09 Lars Holger Hermann Oral dosage forms with reduced potential for drug abuse
WO2011079074A1 (en) * 2009-12-24 2011-06-30 Acura Phamaceuticals, Inc. Pharmaceutical compositions for deterring misuse, abuse, and diversion
US9125867B2 (en) 2010-02-24 2015-09-08 Invincible Biotechnology Diversion- and/or abuse-resistant compositions and methods for making the same
WO2011121824A1 (ja) * 2010-03-29 2011-10-06 アステラス製薬株式会社 口腔内崩壊錠
WO2012061779A1 (en) * 2010-11-04 2012-05-10 Abbott Gmbh & Co. Kg Drug formulations
ES2691982T3 (es) * 2012-11-30 2018-11-29 Acura Pharmaceuticals, Inc. Liberación autorregulada de un principio activo farmacéutico
EP2968178B1 (en) * 2013-03-15 2019-10-09 Inspirion Delivery Sciences LLC Pharmaceuticals comprising a ph-dependent component and ph-raising agent
DE202014010649U1 (de) * 2013-05-06 2016-02-26 Future Motion, Inc. Selbststabilisierendes Skateboard
US10083794B2 (en) * 2015-05-11 2018-09-25 Panasonic Intellectual Property Management Co., Ltd. Metallized film capacitor

Also Published As

Publication number Publication date
CN107595793B (zh) 2020-11-13
JP7660633B2 (ja) 2025-04-11
US9101636B2 (en) 2015-08-11
US9662393B2 (en) 2017-05-30
JP2023175780A (ja) 2023-12-12
US10688184B2 (en) 2020-06-23
US20160199388A1 (en) 2016-07-14
US11857629B2 (en) 2024-01-02
RU2018141241A3 (es) 2021-11-16
JP2016501231A (ja) 2016-01-18
CN107595793A (zh) 2018-01-19
JP6272434B2 (ja) 2018-01-31
AU2018260929B2 (en) 2020-04-30
JP7741698B2 (ja) 2025-09-18
US20240108726A1 (en) 2024-04-04
EP2925304A4 (en) 2016-05-11
US20180326065A1 (en) 2018-11-15
EP3446685A1 (en) 2019-02-27
US20140155388A1 (en) 2014-06-05
CN104968333B (zh) 2018-07-10
JP2017036315A (ja) 2017-02-16
CA2892908A1 (en) 2014-06-05
CN108743549B (zh) 2024-08-06
JP2022025125A (ja) 2022-02-09
AU2020210206A1 (en) 2020-08-20
US20170239354A1 (en) 2017-08-24
US9320796B2 (en) 2016-04-26
CN104968333A (zh) 2015-10-07
IL238713A0 (en) 2015-06-30
JP6974378B2 (ja) 2021-12-01
US20210330793A1 (en) 2021-10-28
JP2018070657A (ja) 2018-05-10
MX2019007956A (es) 2019-09-04
AU2013352162B2 (en) 2018-08-16
EP2925304A1 (en) 2015-10-07
RU2018141241A (ru) 2019-01-24
JP2016166225A (ja) 2016-09-15
MX392839B (es) 2025-03-24
CA2892908C (en) 2016-04-12
EP2925304B1 (en) 2018-09-05
JP2025098253A (ja) 2025-07-01
US20200376123A1 (en) 2020-12-03
CN108743549A (zh) 2018-11-06
US20150374821A1 (en) 2015-12-31
US10441657B2 (en) 2019-10-15
JP6027283B2 (ja) 2016-11-16
AU2020210206B2 (en) 2022-10-13
AU2018260929A1 (en) 2018-11-29
RU2673818C2 (ru) 2018-11-30
JP2019112441A (ja) 2019-07-11
MX2015006613A (es) 2015-11-16
WO2014085599A1 (en) 2014-06-05
AU2013352162A1 (en) 2015-05-28
RU2015124694A (ru) 2017-01-10
ES2691982T3 (es) 2018-11-29
AU2023200124A1 (en) 2023-02-09
AU2025200132A1 (en) 2025-01-30
US11083794B2 (en) 2021-08-10
JP5922851B2 (ja) 2016-05-24

Similar Documents

Publication Publication Date Title
MX366159B (es) Liberacion autorregulada de ingrediente farmaceutico activo.
WO2013170068A3 (en) Nuclear transport modulators and uses thereof
IN2015DN03984A (es)
WO2014205389A8 (en) Nuclear transport modulators and uses thereof
IN2014MN01706A (es)
GB2495676A (en) Use of binders for manufacturing storage stable formulations
EP4650370A3 (en) Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient
EA201400737A1 (ru) Система доставки на основе множества пеллет с немедленным высвобождением активного вещества
TN2014000001A1 (en) A new therapeutical composition containing apomorphine as active ingredient
MX347105B (es) Composiciones farmaceuticas que comprenden hidromorfona y naloxona.
MX2016003754A (es) Una composicion farmaceutica estable que contiene amlodipina y valsartan.
MX2019008817A (es) Formulacion de liberacion prolongada para reducir la frecuencia de miccion y metodo de uso de la misma.
PH12016500865A1 (en) Composite formulation comprising tadalafil and amlodipine
PH12014502836B1 (en) Medicament form for release of active ingredients
WO2012023024A3 (en) Controlled release formulations of dronedarone
HK1212917A1 (zh) 含硫酸特布他林的剂型
PH12015500374A1 (en) Extended release compositions of an aminoalkyl nitrate
MX2014006201A (es) Formas de dosificaciones solidas de imatinib reconstituidas justo antes de usarse.
MX337593B (es) Gemcabeno y derivados para tratar la pancreatitis.
IN2012CH05549A (es)
IN2014CN04119A (es)
WO2013057569A3 (en) Extended release pharmaceutical composition containing amoxicillin and clavulanic acid
TR201009399A2 (tr) Hızlı çözünen efervesan rosuvastatin formülasyonları.
NZ628867A (en) Pharmaceutical formulation containing flupirtine
IN2013MU01330A (es)

Legal Events

Date Code Title Description
FG Grant or registration